Latest news with #Prospera
Yahoo
01-08-2025
- Business
- Yahoo
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
High-impact datasets across heart, kidney and lung at WTC follows two major publications in the American Journal of Transplantation in the last three months AUSTIN, Texas, August 01, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transplant Congress (WTC), taking place August 2 - 6 in San Francisco, CA. The presentations span kidney, heart and lung transplantation and represent one of the most comprehensive collections of data on Natera's Prospera test to date. Highlights include five oral presentations and 11 poster sessions featuring evidence from high-impact studies that support the use of Natera's products, such as: Multiple abstracts from the Trifecta series of studies, including three oral presentations which evaluated Prospera's performance across kidney, heart and lung transplantation. Two posters tied to recently published studies in the American Journal of Transplantation: (1) The prospective, multi-center PEDAL clinical trial, which demonstrated Prospera Kidney's ability to predict long-term outcomes following rejection; and (2) a study on Prospera Heart with Donor Quantity Score (DQS), highlighting its robust performance in detecting allograft rejection. An oral presentation detailing Prospera Kidney's utility in monitoring treatment of chronic antibody-mediated rejection with anti-CD38 monoclonal antibody therapy. These findings were published earlier this month in Kidney International Reports. "We are proud to share 16 presentations across kidney, heart and lung at this major global conference," said Sangeeta Bhorade, M.D., chief medical officer of organ health at Natera. "These new presentations and recent peer-reviewed publications underscore the clinical value of Prospera and affirm our leadership in advancing transplant care through innovation and science." Full list of presentations at WTC include: August 3, 5:35 PM PT | Presentation # OA11.8 (Oral Presentation)Presenter: Patrick T. Gauthier, Study: dd-cfDNA Correlates with T Cell-Mediated Rejection and Parenchymal Injury in Mucosal Biopsies of Lung Transplants August 4, 3:30 PM PT | Presentation # P2.07.92Presenter: Vasanthi Balaraman, of Broad Gene Panel for Kidney Disease in Kidney Transplant Donor Selection: A Case Study August 4, 3:30 PM PT | Presentation # P2.07.165Presenter: Yasar Caliskan, Regarding Use of Genetic Testing in Living Donor Candidate Evaluation: A Survey of US Transplant Center Staff August 4, 3:30 PM PT | Presentation # P2.07.198Presenter: Katelynn S. Madill-Thomsen, All DSA Positive Allows Existing Banff Guidelines to Diagnose Many More Cases of Histologic ABMR Currently Missed Only Because They Are DSA-Negative August 4, 4:41 PM PT | Presentation # OA18.2 (Oral Presentation)Presenter: Krista Lentine, M.D., Practice and Challenges in Managing the Costs of Kidney Paired Donation: A Survey of US Transplant Professionals August 5, 3:30 PM PT | Presentation # P3.03.50Presenter: Suphamai Bunnapradist, the Response to Treatment of Kidney Allograft Rejection with Donor-Derived Cell-Free DNA August 5, 3:30 PM PT | Presentation # P3.03.55Presenter: Paul J. Kim, M.D.A Two-Threshold Algorithm Using Donor-Derived Cell-Free DNA Fraction and Quantity to Detect Acute Rejection After 21 Days Post Heart Transplantation August 5, 3:30 PM PT | Presentation # P3.03.56Presenter: Alan Betensley, M.D., BSE, FCCPMonitoring Changes in Donor-Derived Cell-Free DNA Levels in Treated Lung Allograft Rejection: Pilot Data August 5, 3:30 PM PT | Presentation # P3.03.57Presenter: David J. Ross, M.D., FCCP, FASTCell-Free DNA Does Not Discriminate Acute Rejection from Infection After Lung Transplant: Pilot Study August 5, 3:30 PM PT | Presentation # P3.03.58Presenter: Katherine Vandervest, M.D.'Baseline Lung Allograft Dysfunction' is Associated with Different Cell-Free DNA Dynamics After Lung Transplantation August 5, 3:30 PM PT | Presentation # P3.03.59Presenter: Eileen Hsich, Cell-Free DNA is Not Associated with White Blood Cell Count in Heart Transplant Recipients August 5, 3:30 PM PT | Presentation # P3.03.60Presenter: Navchetan Kaur, of dd-cfDNA Levels in Patients Undergoing Repeat Kidney Transplantation August 5, 3:30 PM PT | Presentation # P3.07.177Presenter: Ziad S. Zaky, Machine Learning with Dynamic Time Warping Helps Understand Longitudinal dd-cfDNA Trajectories in Kidney Transplant Patients August 5, 4:41 PM PT | Presentation # OA36.2 (Oral Presentation)Presenter: Katelynn S. Madill-Thomsen, Relationships Among Tests for Heart Transplant Antibody-Mediated Rejection August 6, 8:44 AM PT | Presentation # OA50.4 (Oral Presentation)Presenter: Katelynn S. Madill-Thomsen, the Hierarchy of Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection August 6, 9:20 AM PT | Presentation # OA50.8 (Oral Presentation)Presenter: Wai-Choong Lye, Monoclonal Antibody Daratumumab for the Treatment of Chronic Active-Antibody Mediated Kidney Allograft Rejection About NateraNatera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking StatementsAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
Yahoo
01-08-2025
- Health
- Yahoo
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
First prospective, multi-center trial to examine how dd-cfDNA can be used in post-rejection patient management AUSTIN, Texas, July 24, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced that the American Journal of Transplantation published findings from the PEDAL study. PEDAL is the first prospective multi-center trial evaluating longitudinal trends of donor-derived cell-free DNA (dd-cfDNA) to determine the prognostic ability of Prospera in assessing outcomes following kidney transplant rejection. PEDAL enrolled 488 kidney transplant recipients from 28 participating U.S. and international transplant centers over 4 years. 66 patients with biopsy-proven acute rejection (BPAR) were longitudinally tested with Prospera in the immediate eight-weeks following BPAR and clinical outcomes were recorded at 12-months. Results from the study demonstrated that Prospera dd-cfDNA trends post-rejection are strongly associated with and prognostic of one-year outcomes. Key findings included: The odds of experiencing positive outcomes after 1 year were 60x higher among patients with low/decreasing Prospera trends. These patients were also 13x more likely to have resolving kidney dysfunction. Conversely, 97.5% (40/41) of cases with sustained elevated/high Prospera trends experienced negative clinical outcomes. Prospera trends were statistically associated with outcomes, suggesting dd-cfDNA may help physicians manage patients post-BPAR. "Following a rejection episode, understanding the long-term prognosis and risk is critical in making ongoing treatment decisions for the patient," said Suphamai Bunnapradist, M.D., professor of medicine at UCLA and principal investigator of the PEDAL study. "These findings make it clear that dd-cfDNA is an important non-invasive tool to provide more accurate risk stratification post-rejection that will enable more personalized patient management and improve long-term graft survival." "This study, the first prospective, multi-center trial to examine this use case, highlights how dynamic monitoring with Prospera provides critical information following a rejection event," said Hossein Tabriziani, M.D., senior medical director of organ health and transplantation at Natera. "By leveraging Prospera, we can empower physicians to make more informed treatment decisions during the immediate post-rejection phase in kidney transplant management." About Prospera The Prospera™ test leverages Natera's core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA (dd-cfDNA) in the recipient's blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for performance regardless of donor relatedness, rejection type, and clinical presentation. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
01-08-2025
- Business
- Business Wire
Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present several new datasets at the 2025 World Transplant Congress (WTC), taking place August 2 - 6 in San Francisco, CA. The presentations span kidney, heart and lung transplantation and represent one of the most comprehensive collections of data on Natera's Prospera test to date. Highlights include five oral presentations and 11 poster sessions featuring evidence from high-impact studies that support the use of Natera's products, such as: Multiple abstracts from the Trifecta series of studies, including three oral presentations which evaluated Prospera's performance across kidney, heart and lung transplantation. Two posters tied to recently published studies in the American Journal of Transplantation: (1) The prospective, multi-center PEDAL clinical trial, which demonstrated Prospera Kidney's ability to predict long-term outcomes following rejection; and (2) a study on Prospera Heart with Donor Quantity Score (DQS), highlighting its robust performance in detecting allograft rejection. An oral presentation detailing Prospera Kidney's utility in monitoring treatment of chronic antibody-mediated rejection with anti-CD38 monoclonal antibody therapy. These findings were published earlier this month in Kidney International Reports. 'We are proud to share 16 presentations across kidney, heart and lung at this major global conference,' said Sangeeta Bhorade, M.D., chief medical officer of organ health at Natera. 'These new presentations and recent peer-reviewed publications underscore the clinical value of Prospera and affirm our leadership in advancing transplant care through innovation and science.' Full list of presentations at WTC include: August 3, 5:35 PM PT | Presentation # OA11.8 (Oral Presentation) Presenter: Patrick T. Gauthier, Ph.D. Trifecta-Lung Study: dd-cfDNA Correlates with T Cell-Mediated Rejection and Parenchymal Injury in Mucosal Biopsies of Lung Transplants August 4, 3:30 PM PT | Presentation # P2.07.92 Presenter: Vasanthi Balaraman, M.D. Role of Broad Gene Panel for Kidney Disease in Kidney Transplant Donor Selection: A Case Study August 4, 3:30 PM PT | Presentation # P2.07.165 Presenter: Yasar Caliskan, M.D. Experiences Regarding Use of Genetic Testing in Living Donor Candidate Evaluation: A Survey of US Transplant Center Staff August 4, 3:30 PM PT | Presentation # P2.07.198 Presenter: Katelynn S. Madill-Thomsen, Ph.D. Calling All DSA Positive Allows Existing Banff Guidelines to Diagnose Many More Cases of Histologic ABMR Currently Missed Only Because They Are DSA-Negative August 4, 4:41 PM PT | Presentation # OA18.2 (Oral Presentation) Presenter: Krista Lentine, M.D., Ph.D. Contemporary Practice and Challenges in Managing the Costs of Kidney Paired Donation: A Survey of US Transplant Professionals August 5, 3:30 PM PT | Presentation # P3.03.50 Presenter: Suphamai Bunnapradist, M.D. Monitoring the Response to Treatment of Kidney Allograft Rejection with Donor-Derived Cell-Free DNA August 5, 3:30 PM PT | Presentation # P3.03.55 Presenter: Paul J. Kim, M.D. A Two-Threshold Algorithm Using Donor-Derived Cell-Free DNA Fraction and Quantity to Detect Acute Rejection After 21 Days Post Heart Transplantation August 5, 3:30 PM PT | Presentation # P3.03.56 Presenter: Alan Betensley, M.D., BSE, FCCP Monitoring Changes in Donor-Derived Cell-Free DNA Levels in Treated Lung Allograft Rejection: Pilot Data August 5, 3:30 PM PT | Presentation # P3.03.57 Presenter: David J. Ross, M.D., FCCP, FAST Cell-Free DNA Does Not Discriminate Acute Rejection from Infection After Lung Transplant: Pilot Study August 5, 3:30 PM PT | Presentation # P3.03.58 Presenter: Katherine Vandervest, M.D. 'Baseline Lung Allograft Dysfunction' is Associated with Different Cell-Free DNA Dynamics After Lung Transplantation August 5, 3:30 PM PT | Presentation # P3.03.59 Presenter: Eileen Hsich, M.D. Donor-Derived Cell-Free DNA is Not Associated with White Blood Cell Count in Heart Transplant Recipients August 5, 3:30 PM PT | Presentation # P3.03.60 Presenter: Navchetan Kaur, Ph.D. Trajectory of dd-cfDNA Levels in Patients Undergoing Repeat Kidney Transplantation August 5, 3:30 PM PT | Presentation # P3.07.177 Presenter: Ziad S. Zaky, M.D. Unsupervised Machine Learning with Dynamic Time Warping Helps Understand Longitudinal dd-cfDNA Trajectories in Kidney Transplant Patients August 5, 4:41 PM PT | Presentation # OA36.2 (Oral Presentation) Presenter: Katelynn S. Madill-Thomsen, Ph.D. Defining Relationships Among Tests for Heart Transplant Antibody-Mediated Rejection August 6, 8:44 AM PT | Presentation # OA50.4 (Oral Presentation) Presenter: Katelynn S. Madill-Thomsen, Ph.D. Defining the Hierarchy of Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection August 6, 9:20 AM PT | Presentation # OA50.8 (Oral Presentation) Presenter: Wai-Choong Lye, M.D. Anti-CD38 Monoclonal Antibody Daratumumab for the Treatment of Chronic Active-Antibody Mediated Kidney Allograft Rejection About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in 'Risk Factors' in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and
Hamilton Spectator
31-07-2025
- Business
- Hamilton Spectator
Prospera Energy Inc. Provides Operations Update
CALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) — Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF) ('Prospera', 'PEI' or the 'Corporation') Operations Update Prospera continues to demonstrate strong operational performance, averaging gross production of 859 boe/d (97% oil) from July 1st to July 23rd. This sustained growth follows the successful completion of numerous projects across the company's properties including well reactivations, rod repairs, sand control upgrades, engine maintenance and tune-ups, lease upgrades, mineral rights acquisitions, coil-tubing cleanouts, and waterflood optimizations. Nine additional wells have come online in the last 10 days and are currently in stages of load fluid recovery or initial optimization. Notably, these figures exclude production from the recently acquired White Tundra Petroleum assets, which remains subject to TSXV acceptance. Comprehensive well-by-well analysis is now being conducted weekly, with production enhancement changes implemented on a daily basis through communication with field operations personnel. Concurrently, Prospera's service rig continues to systematically work through a robust inventory of over 150 remaining workover and reactivation candidates across its heavy oil properties, further enhancing operational efficiency. Prospera's predominantly heavy oil production base continues to operate in favorable pricing conditions with WCS (Western Canadian Select) differentials in an optimal range, contributing to enhanced revenue and cash flow. The Corporation's high netbacks support our strategy to reallocate capital efficiently into high-impact and reliable projects, with 50+ projects now completed and plans finalized for its Q3 and Q4 service rig programs including nine Luseland reactivations that have completed engineering and planning stages. Cuthbert Production at the Cuthbert pool has been rising steadily, averaging 356 boe/d (100% oil) from July 1st to July 23rd. This sustained growth is supported by ongoing waterflood optimization, increased pump speeds, and the completion of critical maintenance across wellsite and battery infrastructure. A high-impact remediation project on the 16-28 HZ well has been successfully completed, involving the installation of a downhole bridge plug to isolate a section of the well previously drilled into coal and water-bearing part of the formation. Additionally, a high-impact remediation project on the 08-02 HZ well has been fully funded and is awaiting mobilization after lease conditions dry up. This project includes a casing cut and cementing to block water production from the heel of the well. Hearts Hill Production at the Hearts Hill pool remains stable, averaging 230 boe/d (91% oil) from July 1st to 23rd. The Corporation is actively advancing waterflood pattern optimization and fluid level drawdown initiatives to enhance reservoir performance. A comprehensive line-by-line review of all pipelines in the area has been completed to confirm injection volumes, validate pipeline integrity, and support the development of a final field reactivation and workover plan. Earlier Sparky zone recompletions continue to deliver consistent oil production, with future Sparky waterflood development held in inventory. Prospera is also actively evaluating uphole recompletion opportunities in the Waseca and Rex zones to further unlock production potential. Luseland The Corporation continues to advance its growth trajectory at the Luseland pool, averaging production of 193 boe/d (100% oil) from July 1st to 23rd. This performance is supported by ongoing workovers, well reactivations, and field optimizations. In the past 10 days, five reactivated wells have been brought online, with two additional wells recently completed under Single Well Battery setups and awaiting start-up. Numerous other wells are currently undergoing optimization, including the installation of recycle pumps, application of sand suspension chemical treatments, increased pump speeds to accelerate fluid drawdown, flushby operations, and well loads to bring sand up the wellbore. These efforts are complemented by various initiatives aimed at reducing operating costs. Prospera's engineering team is focused on well-by-well monitoring of all new reactivations to maximize production rates and enhance reservoir understanding while minimizing well failures and decline rates. Several high-performing Luseland wells are featured in the accompanying Key Wells Report , demonstrating the success of Prospera's strategic focus on revitalizing legacy wells with significant original oil in place (OOIP). By reactivating these assets, the company is effectively converting wells previously classified as No Reserves Associated (NRA) and burdened solely with Asset Retirement Obligations (ARO) into actively producing wells with meaningful Proved Developed Producing (PDP) reserves—resulting in sustainable revenue generation and positive cash flow. Production, Workover Tracker, and Key Wells Report Prospera is enhancing its transparency measures with the publishing of its updated production, workover tracker, and key wells report . Production volumes on each field will continue to be reported on a monthly basis, along with corporate revenue information. A detailed workover tracker will share production rates from all workovers and reactivations completed, with information on capital spend and cumulative production since start-up to be added to the August iteration of this report. Additionally, numerous key wells and their production graphs are explained in detail as the company further proves out its highly capital-efficient workover and reactivation business model. Price Hedging The Corporation is pleased to announce that it has entered into a contract to hedge a portion of its oil production. From September 2025 through February 2026, Prospera has hedged 100 barrels of oil per day at an average price of approximately USD $67.00 per barrel of WTI. This strategic initiative is aimed at providing improved cash flow stability, strengthening corporate governance through proactive risk management, and capitalizing on current favorable market pricing. It represents a disciplined approach to managing commodity price exposure while preserving upside potential across the remainder of PEI's production. Shares for Debt Prospera has entered into agreements with two vendors to settle outstanding trade payables through the issuance of common shares. The first vendor has agreed to settle a total of $28,900.45 through the issuance of 125,000 common shares at a deemed price of $0.231 per share. The second vendor has agreed to settle $7,392.55 through the issuance of 40,000 common shares at a deemed price of $0.185 per share. The shares will be subject to a trading restriction of four months and a day from the date of issuance and are subject to TSXV acceptance. Loan Amendment The Corporation announces a further amendment to its $11,000,000 promissory note, originally dated June 7, 2024, in collaboration with its principal lender. Following previous increases, an additional $2,000,000 has been added, bringing the total principal amount to $18,700,000. The note retains its original terms, including a 12% interest rate and a two-year maturity, with no other changes. The proceeds are earmarked specifically towards production-increasing capital projects. This amendment remains subject to acceptance by the TSXV. Promissory Note Update The Corporation provides an update regarding the previously disclosed one-year secured promissory note on January 9th, 2025. The promissory note component of the offering will now be unsecured. The placement closed with four subscribers, raising aggregate gross proceeds of $900,000. Each unit, priced at $1,000, consists of: (i) a one-year unsecured promissory note with a principal amount of $1,000, carrying a 12% annual interest rate, and (ii) 5,000 common share purchase warrants of the Corporation, exercisable at $0.05 for a period of one year, for a total of 4,500,000 warrants. Subscribers are entitled to a 5% gross overriding royalty (GORR) for every $1,000,000 of principal investment on revenue from all Prospera properties on incremental production above 1,363 barrels per day, calculated on a monthly average until the principal debt is fully repaid. Interest on the notes will accrue and be paid quarterly, accompanied by a 2% facility fee. This offering has been accepted by the TSX Venture Exchange. Insiders have participated in this offering for a principal amount of $800,000, which results in this being a Related Party Transaction pursuant to TSXV Policy 5.9 and MI 61-101. The Corporation is relying upon numerous exemptions under these policies with respect to minority approval and valuation requirements, including those found in section 5.5 (a), (b), and (c) and 5.7 (a) and (b). The following reporting Insiders have participated in this offering: Summerhill Investments Corp. subscribed for $500,000 and was issued an aggregate of 2,500,000 warrants, each exercisable at $0.05 per share for a period of one year from the date of issuance. Mantl Canada Inc. subscribed for $200,000 and was issued an aggregate of 1,000,000 warrants, each exercisable at $0.05 per share for a period of one year from the date of issuance. Countryman Investments Ltd. subscribed for $100,000 and was issued an aggregate of 500,000 warrants, each exercisable at $0.05 per share for a period of one year from the date of issuance. About Prospera Prospera Energy Inc. is a publicly traded Canadian energy company specializing in the exploration, development, and production of crude oil and natural gas. Headquartered in Calgary, Alberta, Prospera is dedicated to optimizing recovery from legacy fields using environmentally safe and efficient reservoir development methods and production practices. The company's core properties are strategically located in Saskatchewan and Alberta, including Cuthbert, Luseland, Hearts Hill, and Brooks. Prospera Energy Inc. is listed on the TSX Venture Exchange under the symbol PEI and the U.S. OTC Market under GXRFF. Prospera reports gross production at the first point of sale, excluding gas used in operations and volumes from partners in arrears, even if cash proceeds are received. Gross production represents Prospera's working interest before royalties, while net production reflects its working interest after royalty deductions. These definitions align with ASC 51-324 to ensure consistency and transparency in reporting. For Further Information: Shawn Mehler, PR Email: investors@ Chris Ludtke, CFO Email: cludtke@ Shubham Garg, Chairman of the Board Email: sgarg@ FORWARD-LOOKING STATEMENTS This news release contains forward-looking statements relating to the future operations of the Corporation and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will,' 'may,' 'should,' 'anticipate,' 'expects' and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding future plans and objectives of the Corporation, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Although Prospera believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Prospera can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, risks associated with the oil and gas industry in general (e.g., operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of reserve estimates; the uncertainty of estimates and projections relating to production, costs and expenses, and health, safety and environmental risks), commodity price and exchange rate fluctuations and uncertainties resulting from potential delays or changes in plans with respect to exploration or development projects or capital expenditures. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Prospera. As a result, Prospera cannot guarantee that any forward-looking statement will materialize, and the reader is cautioned not to place undue reliance on any forward- looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and Prospera does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by Canadian securities law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Cision Canada
09-07-2025
- Business
- Cision Canada
Prospera, Coast Capital and Sunshine Coast credit union members approve merger
Precedent-setting vote marks milestone in forming Canada's largest national purpose-driven credit union SURREY and GIBSONS, BC, July 9, 2025 /CNW/ - Prospera Credit Union ("Prospera"), Coast Capital Savings Federal Credit Union ("Coast Capital") and Sunshine Coast Credit Union ("Sunshine Coast") are excited to announce that members of all three credit unions have voted in favour of merging to form a combined federal credit union. The historic merger will create Canada's largest national purpose-driven credit union by bringing together two provincially regulated credit unions and one federally regulated credit union. To enable the merger with Coast Capital, members of Prospera and Sunshine Coast voted in favour of a two-step process: first, to continue under federal regulation for the sole purpose of amalgamation; and second, to proceed with the merger immediately afterwards. As Coast Capital is already federally regulated, its members were only required to vote on the merger. In all three cases, members voted strongly in favour, surpassing the two-thirds threshold needed to proceed to the next stage of regulatory approvals: Prospera: 75 per cent of votes in favour Coast Capital: 90 per cent of votes in favour Sunshine Coast: 81 per cent of votes in favour. Together, with more than $38.6 billion in assets under administration, 2,500 employees, 730,000 members and 70 branches across the Lower Mainland, Vancouver Island, the Lower Sunshine Coast and the Okanagan, the combined federal credit union will have increased scale and expects to advance investments in more competitive products and services, enhanced digital banking technology and tools, and initiatives that strengthen and uplift local communities. The combined federal credit union will offer a strong and compelling cooperative alternative to the big banks—giving Canadians more choice, more access and more value in how they bank, while setting the stage for future credit union partnerships. The three credit unions will now seek the regulatory approvals necessary to complete the merger. Approvals will be sought from the BC Financial Services Authority and Credit Union Deposit Insurance Corporation with respect to the federal continuances of Prospera and Sunshine Coast, as well as from the Competition Bureau and the federal Minister of Finance. Pending these approvals, it's expected that the combined federal credit union will be formed in 2026. For the time being, members can continue banking as they normally would. The merged credit union will continue to use the trusted and familiar Prospera, Coast Capital and Sunshine Coast brands to ensure a consistent experience for members. In appreciation of member and employee participation in the vote, and reflecting an ongoing commitment to local communities, each credit union will make a donation: Prospera to Special Olympics BC, Coast Capital to the Youth Futures Education Fund and Sunshine Coast Credit Union to the Sunshine Coast Foundation. "I am thrilled we're one step closer to becoming a combined federal credit union," said Gavin Toy, President and CEO, Prospera. "We're building on our strong foundation to deliver greater innovation, deeper impact and financial solutions that truly prioritize our members' best interests." "The successful vote to unite our three credit unions demonstrates strong member support for a national, purpose-led alternative in Canadian banking," said Calvin MacInnis, President and CEO, Coast Capital. "We're grateful for our members' trust and look forward to building a stronger future together." "This is a significant milestone in preserving and amplifying the unique value of cooperative banking," said Shelley McDade, CEO, Sunshine Coast. "Achieving the scale required to invest in our member and employee experience while at the same time honouring our 80+ year legacies is truly a win-win. Thank you to our members for your support and taking this historic and exciting next step with us." About Prospera Credit Union Local banking means investing in Local Good. Built on 80 years of service in local communities, Prospera Credit Union is a community-based, purpose-driven organization that offers a full range of financial products and services. Prospera is one of the largest credit unions in British Columbia, with approximately $9.3 billion in assets under administration and 115,000 members. With 24 branches, Prospera is proud to serve communities throughout the Lower Mainland, Fraser Valley and Okanagan. Prospera has consistently been designated a Great Place to Work, including as one of the "Best Workplaces in BC" and "Best Workplaces in Canada." It's our purpose to build the financial prosperity of our members, enabling thriving local enterprises, financially empowered people and vibrant, healthy communities. About Coast Capital At Coast Capital, we're not dreaming about a better future, we're building one. We're a member-owned financial cooperative with a more than 80-year legacy of unlocking financial opportunities that positively impact people and communities. We believe that every Canadian deserves a financial partner who actually cares how things turn out. Driven by our social purpose, we look at everything we do through the lens of how we can help our nearly 600,000 members, our employees, and communities. We're proud to be a Certified B Corporation™ and part of a global movement building a more inclusive, equitable and regenerative economic system. We're deeply committed to making our financial cooperative a great place to work as demonstrated by some of our accolades. Coast Capital is a platinum member of Canada's Best Managed Companies and one of Canada's Most Admired Corporate Cultures. About Sunshine Coast Credit Union For more than 80 years, Sunshine Coast Credit Union has enriched lives and community where our members live and work. With approximately $1.2 billion in assets under administration, we are a cooperative financial institution delivering personalized financial wellness to close to 17,000 members through three branches, a digital platform and full-service member service centre. Purpose-driven, investing in one another to build a healthy community is how we began, a legacy that continues today.
